纤维蛋白特异性在治疗性溶栓中的重要性以及使用组织型纤溶酶原激活剂和尿激酶原的序贯与协同组合的原理。 - Suppr | 超能文献

Importance of fibrin specificity in therapeutic thrombolysis and the rationale of using sequential and synergistic combinations of tissue plasminogen activator and pro-urokinase.

作者信息

Gurewich V

机构信息

Vascular Laboratory, St. Elizabeth's Hospital, Boston, MA 02135.

出版信息

Semin Thromb Hemost. 1989 Apr;15(2):123-8. doi: 10.1055/s-2007-1002694.

DOI:10.1055/s-2007-1002694

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Importance of fibrin specificity in therapeutic thrombolysis and the rationale of using sequential and synergistic combinations of tissue plasminogen activator and pro-urokinase.纤维蛋白特异性在治疗性溶栓中的重要性以及使用组织型纤溶酶原激活剂和尿激酶原的序贯与协同组合的原理。

Semin Thromb Hemost. 1989 Apr;15(2):123-8. doi: 10.1055/s-2007-1002694.

2

Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.组织型纤溶酶原激活剂（t-PA）、单链尿激酶型纤溶酶原激活剂（scu-PA）和尿激酶序贯输注对兔颈静脉血栓形成模型溶栓的协同作用。

Thromb Haemost. 1987 Oct 28;58(3):943-6.

3

Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.组织型纤溶酶原激活剂（t-PA）和单链尿激酶型纤溶酶原激活剂（scu-PA）：纤维蛋白特异性溶栓治疗的潜力。

Prog Hemost Thromb. 1986;8:1-18.

4

The nature of synergy between tissue-type and single chain urokinase-type plasminogen activators.组织型与单链尿激酶型纤溶酶原激活剂之间协同作用的本质。

Thromb Haemost. 1989 Nov 24;62(3):909-16.

5

Potentiation by heparin fragments of thrombolysis induced with human tissue-type plasminogen activator or human single-chain urokinase-type plasminogen activator.肝素片段对人组织型纤溶酶原激活剂或人单链尿激酶型纤溶酶原激活剂诱导的溶栓作用的增强作用。

Thromb Haemost. 1987 Oct 28;58(3):947-50.

6

Enhanced thrombolysis in plasma and in vivo by single-chain urokinase-type plasminogen activator (scuPA) conjugated to an antifibrin antibody.与抗纤维蛋白抗体偶联的单链尿激酶型纤溶酶原激活剂（scuPA）增强血浆和体内的溶栓作用。

Trans Assoc Am Physicians. 1989;102:7-12.

7

[Thrombolysis using tissue-type plasminogen activator and pro-urokinase: synergism; mutants and hybrids].[使用组织型纤溶酶原激活剂和尿激酶原进行溶栓：协同作用；突变体和杂交体]

Sangre (Barc). 1989 Aug;34(4):297-9.

8

[A hybrid molecule of pro-urokinase and a fibrin-specific, monoclonal antibody fragment is a more effective thrombolytic agent than pro-urokinase in vitro and in vivo].与尿激酶原相比，一种尿激酶原与纤维蛋白特异性单克隆抗体片段的杂交分子在体外和体内都是更有效的溶栓剂。

Verh Dtsch Ges Inn Med. 1990;96:1-3.

9

Fibrin-specific thrombolytic agents.纤维蛋白特异性溶栓剂。

Schweiz Med Wochenschr. 1987 Nov 14;117(46):1791-8.

10

[Combined thrombolysis by pharmacokinetically different plasminogen activators].[通过药代动力学不同的纤溶酶原激活剂进行联合溶栓]

Bioorg Khim. 1998 May;24(5):376-80.

引用本文的文献

1

Venous thrombolysis by tissue-type plasminogen activator in conjunction with the urokinase-fibrinogen covalent conjugate. Effects of potentiation and faster action in dogs.组织型纤溶酶原激活剂联合尿激酶-纤维蛋白原共价共轭物进行静脉溶栓。对犬的增效及更快起效作用

Appl Biochem Biotechnol. 1996 Oct-Nov;61(1-2):123-8. doi: 10.1007/BF02785694.

2

Pro to Gly (P219G) in a silent glycosylation site results in complete glycosylation in tissue plasminogen activator.沉默糖基化位点中的脯氨酸突变为甘氨酸（P219G）导致组织型纤溶酶原激活剂完全糖基化。

Protein Sci. 1993 Jan;2(1):126-7. doi: 10.1002/pro.5560020114.